Abstract 110P
Background
The neutrophil to lymphocyte ratio (NLR) reflects the balance between systemic inflammation and immunity and is emerging as a prognostic biomarker in many diseases. This study aimed to evaluate the prognostic impact of NLR in patients with advanced esophageal cancer.
Methods
A retrospective study of ninety-four stage IV esophageal cancer patients was conducted from January 2018 to December 2020. In our retrospective analysis, the pretreatment NLR of patients was calculated and analyzed. The Youden index was estimated to select the optimal cut-off value for NLR. Univariate and multivariate flexible parametric proportional hazards models with restricted cubic splines (RCS) were used to identify independent prognostic factors, and the Kaplan-Meier method was used to estimate survival curves.
Results
The median follow-up period was 5 months (ranging from 0.06 to 36.92 months). We determined 4.24 as the cut-off value by using the maximum Youden index. Subsequently, patients in the testing group were classified into high PNI and low PNI groups. Kaplan–Meier curves showed the high NLR group had significantly poorer overall survival (OS) than the low NLR group. Median OS in the high NLR group was 3.67 months compared with 7.21 months in the low PNI group (crude HR 1.80, 95% CI 1.14-2.82, p = 0.011). In the multivariate analysis, high NLR was an independent prognostic factor for OS (adjusted HR 1.91, 95% CI 1.15-3.17, p = 0.012).
Conclusions
Pretreatment NLR is a simplified biomarker useful for an independent prognostic factor in advanced stage esophageal cancer and would be easily integrated into clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
108P - A meta-analysis of PD-1 inhibitors for the treatment of advanced esophageal squamous cell carcinoma in second-line setting
Presenter: Barinder Singh
Session: Poster viewing 02
109P - Economic evaluation of second-line treatment for patients with esophageal squamous cell carcinoma: A systematic review
Presenter: Gagandeep Kaur
Session: Poster viewing 02
111P - Bicentric real-life analysis of the molecular portrait of patients with early onset metastatic biliary tract cancer
Presenter: Theresa Schmalfuss
Session: Poster viewing 02
112P - Prognostic role of sarcopenia before neoadjuvant chemoradiotherapy in patients with esophageal cancer: A retrospective study
Presenter: Mastaneh Sanei
Session: Poster viewing 02
113P - Brain metastases in esophageal cancer patients who have been treated with neoadjuvant immunotherapy plus chemotherapy: An inconsiderable complication
Presenter: Jun Liu
Session: Poster viewing 02
114P - Risk factors for oesophageal fistula: A life-threatening complication of treatment for oesophageal cancer
Presenter: Reo Omori
Session: Poster viewing 02
115P - Human epidermal growth factor receptor-2 (HER-2) expression status in patients with cholangiocarcinoma
Presenter: Thanit Imemkamon
Session: Poster viewing 02
116P - Spleen as an organ at risk (OAR) in adjuvant chemoradiotherapy of gastric cancer: Retrospective dosimetric single institutional experience
Presenter: Preethi Shetty
Session: Poster viewing 02
117P - Immunoprofile of adenosquamous carcinoma in gastric cancer
Presenter: Cheng-Han Wu
Session: Poster viewing 02
118P - Association between stomach cancer with behavioral and dietary factors: A case control study from Nepal
Presenter: Arun Shahi
Session: Poster viewing 02